Сахарный диабет и глаукома: взаимосвязи патогенетических механизмов развития заболеваний
Аннотация
Сахарный диабет и глаукома, являясь одними из ведущих причин слепоты и слабовидения, имеют много общих черт: прогрессивное течение, неутешительный прогноз, похожие сосудистые и обменные нарушения, ряд одинаковых факторов риска развития заболеваний. В статье представлен обзор литературы о клинических и экспериментальных данных о патогенетических причинно-следственных связях между этими заболеваниями. Необходимо быть более внимательными к пациентам с сахарным диабетом с целью более раннего диагностирования у них глаукомы.
Об авторах
Е. В. Молчанова
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России
Россия
Россия
Л. М. Габдрахманов
ГБУЗ «Самарская областная клиническая офтальмологическая больница им. Т.И. Ерошевского»
Россия
Россия
Ю. И. Рожко
ГУ «Республиканский научно-практический центр радиационной медицины и экологии человека»
Россия
Россия
А. В. Куроедов
ФКУ «Центральный военный клинический госпиталь им. П.В. Мандрыка» Министерства обороны Российской Федерации; ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Россия
Россия
И. Р. Газизова
ФГБУН РАН «Институт мозга человека им. Н.П. Бехтеревой»
Россия
Россия
Н. А. Бакунина
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Россия
Россия
Ю. П. Сотникова
Хадасса Медикал ЛТД
Россия
Россия
Список литературы
1. NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population - based studies with 4.4 million participants. Lancet. 2016; 387:1513-1530. doi: 10.1016 / S0140-6736(16)00618-8.
2. Ting D.S., Cheung G.C., Wong T.Y. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin. Experiment Ophthalmol. 2016; 44:260-277. doi: 10.1111 / ceo.12696.
3. Astahov Yu.S., Krylova I.S., Shadrichev F.E. Is diabetes a risk factor of primary open-angle glaucoma. Clinical ophthalmology. 2006; 7(3):91-94. (in Russ.)
4. Shen L., Walter S., Melles R.B. et al. Diabetes pathology and risk of primary open-angle glaucoma: evaluating causal mechanisms by using genetic information. Am. J. Epidemiol. 2016; 183:147-155. doi: 10.1093 / aje / kwv204.
5. Mogilevskyy S., Gudzenko K., Panchenko Y., Ziablitsev D. Clinical options for combinations of primary open-angle glaucoma with diabetic retinopathy in patients with type 2 diabetes mellitus. Ophthalmology Eastern Europe. 2021; 11(2):135-145. (in Russ.). doi: 10.34883/PI.2021.11.2.017.
6. Avdeev R.V., Alexandrov A.S., Basinsky A.S., Blyum E.A., Brezhnev A.Yu., Volkov E.N. et al. Risk factors, pathogenic factors in progression of glaucoma by results of multicenter study of Russian Glaucoma Society. Medical and Biological Problems of Life. 2012; 2(8):57-69. (In Russ.).
7. Kuroyedov A.V., Abysheva L.D., Avdeev R.V., Alexandrov A.S., Basinsky A.S., Blyum E.A. et al.Intraocular pressure level in various local hypotensive therapy in primary open-angle glaucoma (multicenter study). Ophthalmology Eastern Europe. 2016; 6(1):27-42. (In Russ.).
8. Rim T.H., Lee S.Y. et al. Increased risk of open-angle glaucoma among patients with diabetes mellitus: a 10-year follow-up nationwide cohort study. Acta Ophthalmol. 2018; 96(8):e1025-e1030. doi: 10.1111/aos.13805.
9. Khatri A., Shrestha J., Thapa M. et al. Severity of primary open-angle glaucoma in patients with hypertension and diabetes. Diabetes Metab Syndr Obes. 2018; 11:209-215. doi: 10.2147/DMSO.S160978.
10. Bonovas S., Peponis V., Filioussi K. Diabetes mellitus as a risk factor for primary open-angle glaucoma: a meta-analysis. Diabet Med. 2004; 21: 609-614.
11. Wong V.H., Bui B.V., Vingrys A.J. Clinical and experimental links between diabetes and glaucoma. Clin Exp Optom. 2011; 94:1:4-23. doi: 10.1111/j.1444-0938.2010.00546.x.
12. Lin H.C., Stein J.D., Nan B. et al. Association of geroprotective effects of metformin and risk of open-angle glaucoma in persons with diabetes mellitus. JAMA Ophthalmol. 2015; 133:915-23. doi: 10.1001 / jamaophthalmol.2015.1440.
13. Shen L., Walter S., Melles R.B. et al. Diabetes pathology and risk of primary open-angle glaucoma: evaluating causal mechanisms by using genetic information. Am. J. Epidemiol. 2016; 183:147-55. doi: 10.1093 / aje / kwv204.
14. Zhao D., Cho J., Kim M.H. et al. Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis. Ophthalmology. 2015; 122:72-78.
15. Dharmadhikari S., Lohiya K., Chelkar V. et al. Magnitude and determinants of glaucoma in type II diabetics: A hospital based cross-sectional study in Maharashtra, India. Oman J. Ophthalmol. 2015; 8:19-23. doi: 10.4103 / 0974-620X.149858.
16. Lipatov D.V. Practical guidance for doctors. Ed. I.I. Dedov, M.V. Shestakova. Moscow: Medicinskoe informacionnoe agentstvo, 2013, 192 p. (in Russ.)
17. Pantalon A., Obadă O., Constantinescu D. et al. Inflammatory model in patients with primary open angle glaucoma and diabetes Int J Ophthalmol. 2019; 12(5):795-801.
18. Vorobieva I.V., Merkushenkova D.A., Kalinina N.I. et al.Interrelation between primary open-angle glaucoma and diabetes. Glaucoma news. 2012; 4 (24): 3-4. (in Russ.)
19. Moshetova L.K., Vorobieva I.V., Parfenova E.V., Merkushenkova D.A., Makarevich P.I., Alekhnovich V.I. Сlinical, functional and morphological results of diabetic macular edema antiangiogenic treatment in patients with diabetes mellitus type two. Ophthalmology in Russia. 2013; 10(1):50-55. (In Russ.). doi: 10.18008/1816-5095-2013-1-50-55.
20. Balashevich L.I., Izmajlov A.S. Diabetic ophthalmopathy. St.Petersburg: Chelovek, 2012, 396 p. (in Russ.).
21. National glaucoma guidelines: for medical practitioners. 4rd ed. Ed. by E.A. Egorov, V.P. Erichev. Moscow: GEOTAR-Media; 2019, 384 p. (In Russ.). doi: 10.33029/9704-5442-8-GLA-2020-1-384.
22. Zeng X.X., Ng Y.K., Ling E.A. Neuronal and microglial response in the retina of streptozotocininduced diabetic rats. Vis Neurosci. 2000; 17:463-471.
23. Barber A.J., Lieth E., Khin S.A. et al. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 1998; 102:783-791.
24. Bui B.V., Loeliger M., Thomas M. et al. Investigating structural and biochemical correlates of ganglion cell dysfunction in streptozotocin-induced diabetic rats. Exp Eye Res. 2009; 88:1076-1083.
25. Sugimoto M., Sasoh M., Ido M. et al. Detection of early diabetic change with optical coherence tomography in type 2 diabetes mellitus patients without retinopathy. Ophthalmologica. 2005; 219:379-385.
26. Sohn E.H., Dijk H.W., Jiao C. et al. Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proc. Natl. Acad. Sci. USA. 2016; 113:E2655-64. doi: 10.1073 / pnas.1522014113.
27. Dijk H.W., Verbraak F.D., Kok P.H. et al. Decreased retinal ganglion cell layer thickness in type 1 diabetic patients. Invest Ophthalmol. Vis Sci. 2010; 51:3660-3665.
28. Phipps J.A., Fletcher E.L., Vingrys A.J. Paired-flash identification of rod and cone dysfunction in the diabetic rat. Invest Ophthalmol. Vis Sci. 2004; 45:4592-4600.
29. Ishii H., Koya D., King G.L. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med. 1998; 76:21-31.
30. Yee P., Weymouth A.E., Fletcher E.L. et al. A role for omega-3 polyunsaturated fatty acid supplements in diabetic neuropathy. Invest Ophthalmol. Vis Sci. 2010; 51:1755-1764.
31. Ramsey D.J., Ripps H., Qian H. An electrophysiological study of retinal function in the diabetic female rat. Invest Ophthalmol Vis Sci. 2006; 47:5116-5124. doi: 10.1167/iovs.06-0364.
32. Spaide R.F. Measurable aspects of the retinal neurovascular unit in diabetes, glaucoma, and controls. Am J Ophthalmol. 2019; 207:395-409. doi: 10.1016 /j.ajo.2019.04.035.
33. Fursova A.Zh., Gamza Yu.A., Derbeneva A.S. et al. Antiangiogenic therapy of diabetic macular edema in patients with primary open-angle glaucoma. The Russian Annals of Ophthalmology. 2020; 136(6):185-194. (in Russ.). doi: 10.17116/oftalma2020136062185.
34. Casson R.J., Chidlow G., Wood J.P. et al. The effect of hyperglycemia on experimental retinal ischemia. Arch Ophthalmol. 2004; 122:361-366.
35. Holman M.C., Chidlow G., Wood J.P. et al. The effect of hyperglycemia on hypoperfusioninduced injury. Invest Ophthalmol. Vis Sci. 2010; 51:2197-2207.
36. Kanamori A., Nakamura M., Mukuno H. et al. Diabetes has an additive effect on neural apoptosis in rat retina with chronically elevated intraocular pressure. Curr Eye Res. 2004; 28:47-54.
37. Huiyuan H., Takuhei Sh., Zangwill L. et al. Progression of primary open-angle glaucoma in diabetic and nondiabetic patients. American Journal of ophthalmology. 2018; 189:1-9. doi: 10.1016 /j.ajo.2018.02.002.
38. Nguyen C.T., Vingrys A.J., Bui B.V. Dietary omega-3 fatty acids and ganglion cell function. Invest Ophthalmol Vis Sci. 2008; 49: 3586-3594.
39. Tezel G., Wax M.B. The immune system and glaucoma. Curr Opin Ophthalmol. 2004; 15:80-84.
40. Bazan N.G. Omega-3 fatty acids, proinflammatory signaling and neuroprotection. Curr Opin Clin Nutr Metab Care. 2007; 10:136-141.
41. Schofield J.D., Liu Y., Rao-Balakrishna P. et al. Diabetes dyslipidemia. Diabetes Ther. 2016; 7:203-219. doi: 10.1007 / s13300-016-0167-x.
42. Alekseev I.B., Kochergin S.A., Vorobyeva I.V. et al. The role of an oxidizing stress in pathogenetic mechanisms of diabetic retinopathy at diabetes mellitus type 2.Russian journal of ophthalmology. 2013; 4:99-102. (in Russ.).
43. Kawasaki A., Otori Y., Barnstable C.J. Müller cell protection of rat retinal ganglion cells from glutamate and nitric oxide neurotoxicity. Invest Ophthalmol. Vis Sci. 2000; 41:3444-3450.
44. Neufeld A.H., Hernandez M.R., Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol. 1997; 115:497-503.
45. Chiou G.C. Review: effects of nitric oxide on eye diseases and their treatment. J Ocul Pharmacol Ther. 2001; 17:189-198.
46. Vorobyeva I.V., Shherbakova E.V. Glaucoma and diabetic retinopathy in patients with diabetes mellitus type 2. Review. Ophthalmology in Russia. 2014; 11(3):4-12. (in Russ.) doi: 10.18008/1816-5095-2014-3-4-12.
47. Silva P.S., Cavallerano J.D., Haddad N.M. et al.Comparison of nondiabetic retinal findings identified with nonmydriatic fundus photography vs ultrawide field imaging in an ocular telehealth program. JAMA Ophthalmol. 2016; 134:330-334. doi: 10.1001 / jamaophthalmol. 2015.5605.
48. Razhko Yu.I., Glushnev I.A., Rebenok N.A., Kuroyedov A.V., Brezhnev A.Yu. Novel approaches to glaucoma treatment (review of patents). National Journal glaucoma. 2021; 20(2):72-80. (In Russ.). doi: 10.25700/2078-4104-2021-20-2-72-80.
49. Ravilla Th. Paradigm shift - For effective management of diabetic retinopathy and glaucoma. Indian J Ophthalmol. 2018; 66(7):893-894. doi: 10.4103 / ijo.IJO_535_18.
Рецензия
Для цитирования:
Молчанова Е.В., Габдрахманов Л.М., Рожко Ю.И., Куроедов А.В., Газизова И.Р., Бакунина Н.А., Сотникова Ю.П. Сахарный диабет и глаукома: взаимосвязи патогенетических механизмов развития заболеваний. Медико-биологические проблемы жизнедеятельности. 2021;(2):28-37.
For citation:
Molchanova E.V., Gabdrakhmanov L.M., Razhko Yu.I., Kuroyedov A.V., Gazizova I.R., Bakunina N.A., Sotnikova Yu.P. Diabetes mellitus and glaucoma: interrelations of pathogenetic mechanisms of disease development. Medical and Biological Problems of Life Activity. 2021;(2):28-37. (In Russ.)
Просмотров: 77
Послать статью по эл. почте 